Bevacizumab in the management of solid tumors

References

• Risau W, Lemmon V. Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev. Biol.125(2), 441–450 (1988).
   PubMed Web of Science ®Google Scholar
• Risau W, Sariola H, Zerwes HG et al. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development102(3), 471–478 (1988).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol.280(6), C1358–C1366 (2001).
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature359, 843–845 (1992).
   PubMed Web of Science ®Google Scholar
• Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc. Res.28, 1176–1179 (1994).
   PubMed Web of Science ®Google Scholar
• Taylor P. VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res.4(Suppl. 3), S99–S107 (2002).
   Google Scholar
• Paleolog E. Angiogenesis in rheumatoid arthritis. Arthritis Res.4(Suppl. 3), S81–S90 (2002).
   PubMedGoogle Scholar
• Witmer AN, Vrensen GFJM, Van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retinal Eye Res.22(1), 1–29 (2003).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285, 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science235, 442–447 (1987).
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst.82, 4–6 (1991).
   Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev.18, 4–25 (1997).
   PubMed Web of Science ®Google Scholar
• Folkman J, Shing Y. Angiogenesis. J. Biol. Chem.267, 10931–10934 (1992).
   PubMed Web of Science ®Google Scholar
• Klagsbrun M, D’Amore PA. Regulators of angiogenesis. Ann. Rev. Physiol.53, 217–239 (1991).
   PubMed Web of Science ®Google Scholar
• Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin. Orthop. (Suppl. 415), S46–S58 (2003).
   Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol.20, 4368–4380 (2002).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23, 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science246, 1306–1309 (1989).
   PubMed Web of Science ®Google Scholar
• Keck PJ, Sauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science246, 1309–1312 (1989).
   PubMed Web of Science ®Google Scholar
• Alon T, Hemo I, Itin A et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med.1, 1024–1028 (1995).
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D et al. Vascular endothelial cell growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature359, 843–845 (1992).
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J.13, 9–22 (1999).
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol.19, 1207–1225 (2001).
   PubMed Web of Science ®Google Scholar
• Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg.82, 864–873 (1995).
   PubMed Web of Science ®Google Scholar
• Akagi Y, Liu W, Xie K et al. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1β. Br. J. Cancer80, 1506–1511 (1999).
   PubMed Web of Science ®Google Scholar
• Potapova O, Fakhrai H, Baird S et al. Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells. Cancer Res.56, 280–286 (1996).
   PubMed Web of Science ®Google Scholar
• Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol.5, 1806–1814 (1991).
   PubMed Web of Science ®Google Scholar
• Tischer E, Mitchell R, Hartman T et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem.266, 11947–11954 (1991).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev.25, 581–611 (2004).
   PubMed Web of Science ®Google Scholar
• Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem.267, 26031–26037 (1992).
   PubMed Web of Science ®Google Scholar
• Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell4, 1317–1326 (1993).
   PubMed Web of Science ®Google Scholar
• Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem.269, 25646–25654 (1994).
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N. Engl. J. Med.324, 1–8 (1991).
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T et al. vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood92, 4150–4166 (1998).
   PubMed Web of Science ®Google Scholar
• Mechtcheriakova D, Schabbauer G, Lucerna M et al. Specificity, diversity, and convergence in VEGF and TNF-α signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J.15, 230–242 (2001).
   PubMed Web of Science ®Google Scholar
• Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood87, 3336–3343 (1996).
   PubMed Web of Science ®Google Scholar
• Pekala P, Marlow M, Heuvelman D et al. Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-α, but not by insulin. J. Biol. Chem.265, 18051–18054 (1990).
   PubMed Web of Science ®Google Scholar
• Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci.108, 2369–2379 (1995).
   PubMed Web of Science ®Google Scholar
• Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol.19, 851–856 (2001).
   PubMed Web of Science ®Google Scholar
• Borgstrom P, Gold DP, Hillan KJ et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res.19, 4203–4214 (1999).
   PubMed Web of Science ®Google Scholar
• Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun.226, 324–328 (1996).
   PubMed Web of Science ®Google Scholar
• Lin P, Sankar S, Shan S et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ.9, 49–58 (1998).
   PubMedGoogle Scholar
• Fairbrother WJ, Christinger HW, Cochran AG et al. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry37, 17754–17764 (1998).
   PubMed Web of Science ®Google Scholar
• Laird AD, Vajkoczy P, Shawver LK et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res.60, 4152–4160 (2000).
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Smolich BD et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des.15, 29–41 (2000).
   PubMedGoogle Scholar
• Fong TA, Shawyer LK, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res.59, 99–106 (1999).
   PubMed Web of Science ®Google Scholar
• Vajkoczy P, Menger MD, Vollmar B et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia1, 31–41 (1999).
   PubMedGoogle Scholar
• Wedge SR, Ogilvie DJ, Dukes M et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad spectrum antitumor efficacy. Cancer Res.60, 970–975 (2000).
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57, 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther.288, 371–378 (1999).
   PubMed Web of Science ®Google Scholar
• Data on file. South San Francisco, CA, Genentech Inc. (2002).
   Google Scholar
• Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol.19, 843 (2001).
   PubMed Web of Science ®Google Scholar
• Avastin®, package insert. Genentech Inc., CA, USA (2006).
   Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol.22(11), 2184–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res.64, 3731–3736 (2004).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol.30(Suppl. 16), 117–124 (2003).
   PubMed Web of Science ®Google Scholar
• Bergsland E, Dickler M. Maximizing the potential of bevacizumab in cancer treatment. Oncologist9(Suppl. 1), 36–42 (2004).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz H, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21, 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II Trial. J. Clin. Oncol.23, 3697–3705 (2005).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J. Clin. Oncol.23(Suppl. Pt 1), S16 (2005).
   Google Scholar
• Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology69(Suppl. 3), 25–33 (2005).
   PubMed Web of Science ®Google Scholar
• Skillings RJ, Johnson HD, Miller K et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 3019).
   Google Scholar
• Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J. Clin. Oncol.23, 4853–4855 (2005).
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J. Clin. Oncol.24(Suppl. Pt 1) S18 (2006).
   Google Scholar
• Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch. Neurol.63, 1475–1478 (2006).
   PubMed Web of Science ®Google Scholar
• Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med.354, 980 (2006).
   PubMed Web of Science ®Google Scholar
• Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. Oncologist11, 85–86 (2006).
   PubMed Web of Science ®Google Scholar
• Traina TA, Norton L, Drucker K, Singh B. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist11, 1070–1071 (2006).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Diaz-Rubio E et al. First efficacy and safety results from XELOX-1/NO16966, a randomized 2 x 2 factorial Phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann. Oncol.17(Suppl. 9), LBA3 (2006).
   Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.23, 792–799 (2005).
   PubMed Web of Science ®Google Scholar
• Ramaswamy B, Elias AD, Kelbick NT et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res.12(10), 3124–3129 (2006).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Gray R, Schiller JH, Perry M, Sandler A, Johnson D. ECOG 4599 Phase III trial of carboplatin and paclitaxel ±bevacizumab: subset analysis of survival by gender. J. Clin. Oncol.24(Suppl. 18), 7036 (2006).
   Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355, 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Miller KD, Wang M, Gralow J et al. A randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial conducted by the Eastern Cooperative Oncology Group (E2100). Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA (2005).
   Google Scholar
• Burger RA, Sill M, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol.23(Suppl. Pt 1), S16 (2005).
   Google Scholar
• Garcia AA, Oza AM, Hirte H et al. Interim report of a Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial. J. Clin. Oncol.23(Suppl. Pt 1), S16 (2005).
   Google Scholar
• Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl Acad. Sci.100(22), 12917–12922 (2003).
   PubMed Web of Science ®Google Scholar
• Hamano Y, Sugimoto H, Soubasakos MA et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res.64, 1570–1574 (2004).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Sosman JA, Spigel DR et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). J. Clin. Oncol.23 (2004) (Abstract 4502).
   Google Scholar
• Ning YM, Arlen P, Gulley J et al. A Phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). J. Clin. Oncol.24(Suppl. 18), 13037 (2006).
   Google Scholar
• Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer107, 67–74 (2006).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J. Clin. Oncol.24(Suppl. 18), 1506 (2006).
   Google Scholar
• Kirkpatrick J, Desjardins A, Vredenburgh JJ et al. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: study of cases. J. Clin. Oncol.24(Suppl. 18), 11522 (2006).
   Google Scholar
• Welch S, Kocha W, Rumble RB, Spithoff K, Maroun J; and the Gastrointestinal Cancer Disease Site Group. The role of bevacizumab (Avastin) combined with chemotherapy in the treatment of patients with advanced colorectal cancer. Cancer Care Ontario23, 2–25 (2005).
   Google Scholar